Collectively, these results suggest that CD80-expressing cancer cells are present in some solid epithelial cancers and some blood cancers, supporting the potential to select patients based on cancer cell CD80 expression for treatment with a FAK inhibitor. Here, PTK2 is linked to hematopoietic and lymphoid system neoplasm.